Table 2.

Annotated plasma metabolites that were differentially expressed (all three p-values ≤0⋅05) at higher or lower levels in Child Pugh B (CP B) vs. Child Pugh A (CP A) HCC patients at baseline. The p-values presented are from the Wilcoxon rank sum test. Metabolites with all three p-values ≤0⋅05 and q-value ≤0⋅1 are marked ^‡. Metabolites identified by GC/MS are marked ^#, while those identified by LC/MS are not marked.

AT BASELINE
High expressing metabolites in CP B vs. CP A				Low expressing metabolites in CP B vs. CP A
Identity†	Fold diff*	p-value	q-value	Identity†	Fold diff*	p-value	q-value
C10	1⋅29	0⋅017	0⋅41	2-ketoisocaproic acid#	0⋅67	0⋅002	0⋅16
C10:1	1⋅39	0⋅007	0⋅30	Alanine	0⋅69	0⋅0007	0⋅11
C12	1⋅27	0⋅014	0⋅40	Decanoic acid	0⋅88	0⋅008	0⋅24
C12:1	1⋅45	0⋅002	0⋅15	Isoleucine	0⋅64	0⋅017	0⋅42
C14	1⋅26	0⋅011	0⋅35	Gluconic acid lactone#	0⋅67	0⋅046	0⋅50
C14:1-OH	1⋅49	0⋅001	0⋅12	LysoPC a C14:0	0⋅91	0⋅010	0⋅34
C14:2-OH	1⋅58	0⋅0007	0⋅11	LysoPC a C16:0	0⋅65	0⋅012	0⋅37
C16	1⋅48	0⋅003	0⋅21	LysoPC a C16:1	0⋅59	0⋅010	0⋅35
C16:1	1⋅76	0⋅001	0⋅14	LysoPC a C18:2	0⋅72	0⋅019	0⋅45
C16:2	1⋅45	0⋅042	0⋅49	LysoPC a C20:3	0⋅70	0⋅026	0⋅37
C18	1⋅40	0⋅044	0⋅49	LysoPC a C20:4	0⋅67	0⋅047	0⋅50
C18:1	1⋅66	0⋅0006	0⋅11	LysoPC a C26:0	0⋅64	0⋅0009	0⋅12
C18:2	1⋅50	0⋅0004	0⋅24	LysoPC a C26:1	0⋅62	0⋅005	0⋅24
C2	1⋅60	0⋅014	0⋅40	LysoPC a C28:0	0⋅64	0⋅001	0⋅12
C5:1-DC	1⋅35	0⋅021	0⋅48	PC aa C24:0	0⋅64	3⋅96E-05	0⋅008‡
C6:1	1⋅83	0⋅0002	0⋅04‡	PC aa C26:0	0⋅70	0⋅002	0⋅11
PC aa C32:0	1⋅64	0⋅0008	0⋅09‡	PC aa C32:3	0⋅72	0⋅030	0⋅50
PC aa C40:2	1⋅23	0⋅012	0⋅37	PC aa C34:4	0⋅60	0⋅007	0⋅22
PC aa C42:0	1⋅31	0⋅011	0⋅25	PC aa C36:4	0⋅68	0⋅039	0⋅50
PC aa C42:4	1⋅21	0⋅026	0⋅50	Sarcosine	0§	3⋅72E-05	<0⋅001‡
PC ae C32:1	1⋅54	7⋅46E-05	0⋅033‡	Uracil#	0⋅63	0⋅003	0⋅21
PC ae C32:2	1⋅19	0⋅016	0⋅42	Valine	0⋅81	0⋅009	0⋅33
PC ae C34:1	1⋅41	0⋅019	0⋅15
PC ae C34:3	1⋅27	0⋅032	0⋅41
PC ae C36:0	1⋅29	0⋅036	0⋅48
PC ae C42:4	1⋅33	0⋅004	0⋅23
PC ae C42:5	1⋅20	0⋅008	0⋅31
PC ae C44:5	1⋅29	0⋅017	0⋅37
PC ae C44:6	1⋅31	0⋅013	0⋅40
SDMA	1⋅75	0⋅002	0⋅14
SM C16:0	1⋅22	0⋅013	0⋅35
SM C26:1	1⋅33	0⋅005	0⋅24

^⁎Fold diff, fold difference between CP B vs. CP A HCC patients.

^†C10, decanoylcarnitine; C10:1, decenoylcarnitine; C12, dodecanoylcarnitine; C12:1, dodecenoylcarnitine; C14, tetradecanoylcarnitine; C14:1-OH, hydroxytetradecenoylcarnitine; C14:2-OH, hydroxytetradecadienylcarnitine; C16, hexadecanoylcarnitine; C16:1, hexadecenoylcarnitine; C16:2, hexadecadienylcarnitine; C18, octadecanoylcarnitine; C18:1, octadecenoylcarnitine; C18:2, octadecadienylcarnitine; C2, acetylcarnitine; C5:1-DC, glutaconylcarnitine, C6:1, hexenoylcarnitine; PC aa, phosphatidylcholine diacyl, PC ae, phosphatidylcholine acyl-alkyl; SDMA, symmetric dimethyl arginine; SM, sphingomyelin.

^‡Metabolites with all three p-values ≤0⋅05 and q-value <0⋅1.

^§There was no expression of sarcosine in CP B HCC patients. As such, when dividing no expression in CP B patients by some expression in CP A HCC patients, the fold difference appeared as 0.

^#Metabolites identified by GC/MS. Metabolites identified by LC/MS are not marked.